Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes

Journal of Investigative Dermatology

Volumn 135, Issue 9, 2015, Pages 2266-2272

  Fang, Shenying ^a   Wang, Yuling ^a   Chun, Yun S ^b   Liu, Huey ^a   Ross, Merrick I ^a   Gershenwald, Jeffrey E ^a   Cormier, Janice N ^a   Royal, Richard E ^a   Lucci, Anthony ^a   Schacherer, Christopher W ^a   Reveille, John D ^c   Chen, Wei ^a   Sui, Dawen ^a   Bassett, Roland L ^a   Wang, Li E ^a   Wei, Qingyi ^d   Amos, Christopher I ^e   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Virginia Piper Cancer Institute   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12P40; ISOLEUCINE; PHENYLALANINE; VALINE; IL12B PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SUSCEPTIBILITY; CHROMOSOME 5; CHROMOSOME 5Q; CONTROLLED STUDY; EBF1 GENE; FEMALE; FLJ31951 GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MISSENSE MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; UBLCP1 GENE; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; REPRODUCIBILITY; SKIN TUMOR; SURVIVAL;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84939463494     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.138     Document Type: Article

References (25)

1. Abdi K, Singh NJ, Spooner E et al. (2014) Free IL-12p40 monomer is a polyfunctional adaptor for generating novel IL-12-like heterodimers extracellularly. J Immunol 192: 6028-36
2. Altare F, Jouanguy E, Lamhamedi S et al. (1998) Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 10: 413-7
3. Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322: 881-8
4. Amos CI, Wang LE, Lee JE et al. (2011) Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 20: 5012-23
5. Aulchenko YS, Struchalin MV, van Duijn CM (2010) ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11: 134
6. Cargill M, Schrodi SJ, Chang M et al. (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasisrisk genes. Am J Hum Genet 80: 273-90
7. Carreno BM, Becker-Hapak M, Huang A et al. (2013) IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 123: 3383-94
8. Casanova JL (2001) Mendelian susceptibility to mycobacterial infection in man. Swiss Med Wkly 131: 445-54
9. Conway C, Beswick S, Elliott F et al. (2010) Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 49: 425-38
10. Cooper AM, Khader SA (2007) IL-12p40: an inherently agonistic cytokine. Trends Immunol 28: 33-8
11. Fallarino F, Uyttenhove C, Boon T et al. (1996) Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 156: 1095-100
12. Fang S, Han J, Zhang M et al. (2013) Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One 8: e85642
13. Fang S, Wang Y, Chun Y et al. (2014) The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136: 1874-80
14. Hamid O, Robert C, Daud A et al. (2013) Safety and tumor responses with lambrolizumab (Anti-D-1) in melanoma. N Engl J Med 369: 134-44
15. Langowski JL, Zhang XQ, Wu LL et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461-5
16. Langrish CL, McKenzie BS, Wilson NJ et al. (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96-105
17. Li Y, Willer C, Sanna S et al. (2009) Genotype imputation. Annu Rev Genomics Hum Genet 10: 387-406
18. Liu JZ, Mcrae AF, Nyholt DR et al. (2010) A versatile gene-based test for genome-wide association studies. Am J Hum Genet 87: 139-45
19. Nagai H, Oniki S, Fujiwara S et al. (2010) Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy 2: 697-709
20. Quaglino E, Rovero S, Cavallo F et al. (2002) Immunological prevention of spontaneous tumors: a new prospect? Immunol Lett 80: 75-9
21. Randolph AG, Lange C, Silverman EK et al. (2004) The IL12B gene is associated with asthma. Am J Hum Genet 75: 709-15
22. Riley JL (2013) Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 369: 187-9
23. Strange A, Capon F, Spencer CCA et al. (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42: 985-U106
24. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-46
25. Wolchok JD, Kluger H, Callahan MK et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-33